A novel technique that implants the balloon-expandable valve just 1.5 mm under the noncoronary cusp improves outcomes in transcatheter aortic valve replacement, finds a new Cleveland Clinic study.
Among patients 55 or younger, TAVR use is growing but carries a higher risk of stroke than surgical aortic valve replacement, finds an STS database analysis. We explore evolving options for AVR in younger patients.
Mortality differs from state to state and between nonwhite and white demographic groups, finds a new analysis of nationwide data since 2008.
A pooling of data from several PARTNER trials shows that chronic kidney disease was highly prevalent and that TAVR was associated with stable or improved kidney function in a large majority of cases.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
At centers of excellence, contemporary outcomes of surgical aortic valve replacement have improved to the point that STS risk score is no longer a useful predictor, a Cleveland Clinic study concludes.
Findings of better post-TAVR survival in mixed aortic valve disease compared with pure aortic stenosis suggest that hearts already exposed to aortic regurgitation may better tolerate mild post-TAVR regurgitation.
The time interval between left ventricular and aortic systolic pressure peaks is associated with severity of aortic stenosis, a study suggests. The effect is strongest in patients with low mean pressure gradient.
Two trials comparing transcatheter (TAVR) with surgical aortic valve replacement in patients at low surgical risk found TAVR to yield equal or better outcomes. While a new indication seems certain, some key questions remain.
Heterogeneity is the rule with bicuspid aortic valves, so optimal surgical solutions vary by patient. Our experts share experience-based guidance for managing various presentations of BAV and aortopathy.
A new analysis of the large TVT Registry provides the strongest evidence to date of a prognostic benefit from renin-angiotensin system inhibitor therapy following transcatheter aortic valve replacement.